The effect of nitro-oleic versus losartan in diabetic nephropathy: modulation of parathyroid hormone-related protein by Mohammed, A. S. et al.
Folia Morphol. 
 Vol. 78, No. 1, pp. 79–90
DOI: 10.5603/FM.a2018.0057
Copyright © 2019 Via Medica
ISSN 0015–5659 
journals.viamedica.pl
O R I G I N A L    A R T I C L E
79
Address for correspondence: Dr. B.E. Aboulhoda, Department of Anatomy and Embrology, Faculty of Medicine, Cairo University, Cairo, Egypt, 
e-mail: doctor.basma@hotmail.com
The effect of nitro-oleic versus losartan  
in diabetic nephropathy: modulation  
of parathyroid hormone-related protein
A.S. Mohammed1, N.B. Sadek1, M.A. Eshra1, E.A.H. Khowailed1, L.A. Rashed2, B.E. Aboulhoda3
1Department of Physiology, Faculty of Medicine, Cairo University, Egypt
2Department of Biochemistry, Faculty of Medicine, Cairo University, Egypt
3Department of Anatomy and Embrology, Faculty of Medicine, Cairo University, Egypt
[Received: 3 May 2018; Accepted: 18 May 2018]
Background: Parathyroid hormone-related protein (PTHrP) involvement in the 
mechanisms related to angiotensin II (AngII)-induced renal injury has become an 
emerging concern. The current study was thus designed to compare the possible 
preventive and therapeutic effect of AngII antagonists, losartan and nitro-oleic 
(NO2-OA) acid, on diabetic nephropathy (DN) and evaluate their effect on PTHrP 
modulation as well as on the functional and histopathological parameters in the 
kidney of diabetic rats.
Materials and methods: Forty eight adult male Sprague Dawley rats were divided 
into control group, DN group, pre-diabetic nephropathy (pre-DN) losartan group, 
pre-diabetic nephropathy nitro-oleic acid (pre-DN NO2-OA) group, post-diabetic 
nephropathy (post-DN) losartan and post-diabetic nephropathy nitro-oleic acid 
(post-DN NO2-OA) groups. At the end of the study, systolic blood pressure (SBP), 
serum fasting glucose, glomerular filtration rate (GFR), urea, urea albumin excretion 
(UAE), serum angiotensin, renal PTHrP gene expression and correlations between 
PTHrP and SBP, serum glucose, AngII and kidney functions were evaluated. Histo-
logical examination, Masson’s trichrome, periodic acid-Schiff staining as well as 
morphometric analysis and histopathological scoring for tubular and glomerular 
parameters have been carried out.
Results: Prophylactic losartan and NO2-OA were associated with improvement 
in SBP, serum glucose, urea, GFR, UAE, with reduction in serum AngII and PTHrP 
overexpression observed in diabetic kidney. Treatment with losartan and NO2-OA 
showed the same effect except that post-DN NO2-OA showed no significant effect 
regarding kidney function. Strong correlations were observed between PTHrP 
and SBP, serum glucose, AngII and kidney functions. Histopathological results 
revealed obvious improvement in glomerulosclerosis, vascular and tubular injury 
parameters in prophylactic groups especially with losartan.
Conclusions: Both pre and post-DN losartan, NO2-OA may have a potential role 
in protection and regression of DN through reduction of PTHrP overexpression. 
(Folia Morphol 2019; 78, 1: 79–90)
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INTRODUCTION
The treatment guidelines for diabetic nephro-
pathy (DN) always focus on slowing the progression 
of nephropathy by controlling glucose levels and 
decreasing blood pressure. However, this remains 
always suboptimal. Thus, it’s become more impor-
tant to focus on novel molecular mechanisms and 
treatment modalities [21]. One of those newly evolv-
ing lines is the renal interaction between the renin–
angiotensin–aldosterone system (RAS), parathyroid 
hormone related protein (PTHrP) and angiotensin II 
(AngII) in the kidney [13]. Current concepts indicate 
that PTHrP is a regulating factor, being more similar 
to other known growth factors and cytokines than 
to parathyroid hormone [3].
Based on the role of the RAS as crucial pathway in-
volved in pathogenesis and progression of DN, along 
with the previous studies demonstrating interaction 
between PTHrP and AngII in the kidney [13, 25], heart 
[19] and in vascular smooth muscle cells [14, 16] the 
current study aimed at evaluating the effect AngII 
antagonists in an experimental model of DN using 
one pharmacological drug, losartan as an angiotensin 
receptor blocker (ARB), and a non-pharmacological 
agent, nitro-oleic acid (olive oil), guided by the recent 
recommendations provided by American Diabetic 
Association regarding the value of ARBs in DN [21].
Losartan is a reversible, competitive inhibitor of 
the AT1 receptor (AT1R) while nitro oleic acid (NO2-
-OA) binds directly to the AT1R without interfering 
with AngII binding, suggesting that molecular inter-
actions between NO2-OA and AT1R are likely to differ 
from ARBs competitive inhibition [27]. 
The current study was designed to evaluate the 
possible preventive and therapeutic effects of losartan 
and NO2-OA on the functional and histopathological 
parameters of DN and to elucidate the effect of those 
drugs on PTHrP modulation in an attempt to provide 
appropriate ground for better management of DN. 
MATERIALS AND METHODS
Materials
Chemicals were purchased from Sigma (St. Louis, 
MO, USA). (1) Streptozotocin (STZ) powder, dissolved 
in fresh 0.05 M citrate buffer, pH = 4.5 and immedi-
ately injected intraperitoneally (i.p.) as recommended 
by the National Institute of Diabetes Animal Models 
of Diabetic Complications Consortium. (2) Losartan 
10 mg/kg dissolved in 1 mL saline in oral gavage [12]. 
(3) 10-Nitro oleic acid was infused at 5 mg/kg/day via 
osmotic minipump [12].
Experimental animals
Forty-eight adult male Sprague Dawley rats (150–
200 g) were purchased from the animal care unit. All 
experimental procedures were carried out according 
to guidelines for care and use of laboratory animals 
published by the United States National Institute of 
Health (NIH 1985). The study was approved by Kasr 
al-ainy Ethical Committee, Faculty of Medicine, Cairo 
University. Animals had free access to food and water.
Preparation of diabetic rat
The animals were injected with STZ (50 mg/kg, 
i.p.) [7]. Five days after injection, the rats with fasting 
blood glucose higher than 200 mg/dL were consid-
ered diabetic and were used for the experiment which 
lasted for 8 weeks. 
Animal groups
Animals were divided into the following groups 
8 rats each:
 — Control group;
 — Diabetic nephropathy (DN) group: Diabetic rats 
that received equal amount of vehicle. The esti-
mated duration for developing nephropathy is 
4 weeks after induction of diabetes [20]. Nephro-
pathy was confirmed by significant increase in 
proteinuria and serum creatinine;
 — Pre-DN losartan group (losartan prophylactic 
group): received losartan 10 mg/kg dissolved in 
1 mL saline in oral gavage [12], as prophylaxis 
to DN, starting from the onset of diabetes, and 
continued for 4 weeks (the estimated time for oc-
currence of nephropathy) and then the rats were 
left without any medications till the end of study;
 — Pre-DN NO2-OA (NO2-OA prophylactic group): 
received NO2-OA infused at 5 mg/kg/day via os-
motic minipump, as prophylaxis to DN in the same 
fashion as the losartan prophylactic group;
 — Post-DN losartan (losartan treatment group): re-
ceived losartan 10 mg/kg dissolved in 1 mL saline 
in oral gavage [12] for 4 weeks, started after the 
occurrence of diabetic nephropathy till the end 
of the study;
 — Post-DN NO2-OA (NO2-OA treatment group): 
received NO2-OA infused at 5 mg/kg/day via os-
motic minipump for 4 weeks, started after the 
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occurrence of diabetic nephropathy till the end 
of the study. 
Experimental design
The animals were daily observed for signs of mor-
bidity and mortality. There was neither mortality nor 
changes in food and water consumption and health 
status in the studied animals. At the end of the study, 
all rats were subjected to overnight fasting; blood 
samples were collected from the retro-orbital plexus 
for assessment of fasting serum glucose level, blood 
urea nitrogen (BUN), serum angiotensin and plas-
ma creatinine for assessing glomerular filtration rate 
(GFR). Urine samples were collected for measuring 
creatinine in urine and 24 h urine were collected, for 
measuring GFR and urinary albumin excretion (UAE). 
Systolic blood pressure (SBP) in rats was measured. 
Finally, kidney tissue samples were extracted for his-
topathological and quantitative real-time polymerase 
chain reaction (PCR) gene expressions of PTHrP.
Measurement of SBP
Using the Power lab data acquisition system (AD 
instruments; Pty Ltd., Australia); an electronic version 
of the traditional sphygmomanometer cuff method. 
Biochemical assessment 
Measurement of fasting serum glucose. The 
glucose was measured colorimetrically after oxidation 
of glucose. The absorbance of standard and samples 
were measured spectrophotometrically against blank 
at 500 nm wavelength.
Determination of kidney functions. (1) Measure- 
ment of UAE using Albuwell M Kit: Murine Microal-
buminuria ELISA. Before sampling, rats were de-
prived from food for 1 day with free access to water. 
(2) Measurement of serum creatinine and BUN using 
kits (Bioclin, Santa Coloma, Spain) with absorbance 
at 340 mm based on the reaction between ammonia 
and alpha-ketoglutaric acid when urea is hydrolysed. 
(3) Determination of GFR was done by calculating the 
creatinine clearance: Creatinine clearance = (urine 
level of creatinine × 24 h urine volume) ÷ (plasma 
level of creatinine × 24 × 60). 
Measurement of angiotensin II enzyme. Using 
enzyme Immunoassay (EIA) Kit (RayBio®).
Quantitative analysis of gene expression of 
PTHrP by real time PCR. Total RNA was extracted 
from kidney tissue homogenate using Qiagen tissue 
extraction kit (Qiagen, USA) according to manufac-
turer’s instruction. Complementary DNA was synthe-
sized from 1 μg RNA using SuperScript III First-Strand 
Synthesis System as described in the manufacturer’s 
protocol (#K1621, Fermentas, Waltham, MA, USA). 
Real-time PCR amplification and analysis were 
performed using an Applied Biosystem with software 
version 3.1 (StepOne™, USA). The reaction contained 
gene-specific primer pairs for PTHrP with following 
sequence Sense 5-TGGTGTTCCTGCTCAGCTA-3, an-
tisense 5-CCTCGTCGTCTGACCCAAA-3 and b-actin 
sense: 5’-CAG GAT GGC GTG AGG GAG AGC-3’, an-
tisense: 5’- , 5’-AAG GTG TGA TGG TGG GAA TGG-3’-. 
Relative expression of gene mRNA was calculated. All 
values were normalised to b-actin which was used as 
the control housekeeping gene and reported as fold 
change over background levels.
Histopathological examination
Kidneys from all groups were dissected and fixed 
immediately in 10% formol saline. Then the specimens 
were washed, dehydrated in ascending grades of eth-
anol, cleared in xylene and impregnated in paraffin. 
Sections of 5 μm thickness were cut and subjected to 
haematoxylin and eosin (H&E), Masson’s trichrome 
(MT) and periodic acid-Schiff (PAS) staining.
Quantitative morphometric analysis
All histomorphometric parameters were estimated 
via the Leica image analyser software programme 
(Leica Qwin 500C Ltd., Cambridge, England) in 10 
non-overlapping randomly-selected fields. 
For H&E-stained sections. The measured param-
eters were Bowman’s spaces, glomerular areas, tu-
bular diameter, tubular epithelial height and vascular 
congestion area per cent.
For MT-stained sections. The area per cent of col-
lagen fibres was measured using the measuring field 
menu; the area and area percentage were masked by 
blue binary colour and estimated using the image 
analyser.
For PAS-stained sections. Length of PCT brush 
border and PAS optical density were assessed.
Histopathology scoring. Histopathology scoring 
was carried out using a scoring system reflecting 
the grading of tubular necrosis and cast formation 
in H&E stained sections as previously described [4]: 
0 (none), 1 (< 10%), 2 (10 – < 25%), 3 (25 – < 45%), 
4 (45 – < 75%), and 5 (> 75%). 
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Statistical methods
Data were analysed using statistical package SPSS 
version 24. Data were summarised using mean and 
standard deviation. Comparisons between groups 
were done using ANOVA with multiple comparisons 
Bonferroni post hoc testing. Correlations between 
variables were done using Pearson correlation coef-
ficients. P-values < 0.05 were considered statistically 
significant.
RESULTS
Changes in fasting serum glucose level
Induction of diabetes resulted in significant increase 
in serum glucose level. Serum glucose levels in pre-DN 
losartan and pre-DN (NO2-OA) groups were significantly 
reduced compared to diabetic group. However, prophy-
lactic losartan showed significant improving compared 
to prophylactic NO2-OA (Fig. 1A).
Post-DN losartan and post-DN (NO2-OA) group 
showed significant decline in serum glucose, with 
no significant difference in relation to each other.
Results of SBP
Systolic blood pressure level was significantly in-
creased in diabetic rats. Prophylactic losartan and 
NO2-OA resulted in significant improvement of SBP, 
with much more improvement with losartan (Fig. 1B). 
Treatment of diabetic rats with either losartan or 
NO2-OA showed significant reduction in SBP.
Results of kidney function parameters:  
UEA, GFR, and urea
Kidney function parameters were significantly 
deteriorated in diabetic rats relative to control rats 
with increase in urea and UAE and decrease in GFR 
(Fig. 1C–E).
Prophylactic losartan showed partial protection 
from DN presented by significant decline in urea and 
UAE and significant rise to GFR. Similarly, prophylactic 
NO2-OA showed significant improvement in these 
parameters. Losartan treatment showed significant 
lower urea and UAE and higher GFR.
Changes in serum angiotensin and  
PTHrP expression in renal tissue
Serum angiotensin and PTHrP expression showed 
a significant increase in diabetic rats (Fig. 1F). After 
prophylactic administration of both losartan and 
NO2-OA, serum angiotensin level decreased signif-
icantly and PTHrP expression recovered significantly. 
Regarding the treatable effect of both drugs, the 
reduced levels of serum angiotensin and PTHrP ex-
pression were significantly improved compared to 
diabetic rats. Only angiotensin level showed signifi-
cant difference in post-DN losartan relative to post-DN 
NO2-OA group with non-significant increase in PTHrP.
Correlation studies showed that PTHrP showed 
a strong positive correlation with angiotensin, urea 
and UAE and negative correlation with GFR as shown 
in Figure 2.
Histopathological results
Examination of H&E stained sections (Fig. 1H, I; 3). 
Examination of the DN group revealed pleopatholog-
ical glomerular and tubular changes with statistically 
significant deterioration in tubular necrosis and cast 
formation. Comparing the protective role of losar-
tan and NO2-OA demonstrated that pre-DN losartan 
resulted in preservation of glomerular and tubular 
architectural patterns while NO2-OA showed only 
partial conservation. Losartan or NO2-OA treatment 
after DN slightly improved glomerulosclerosis.
Assessment of vasculopathy in H&E stained 
sections (Fig. 3). The DN group exhibited severely 
dilated congested blood vessels surrounded by hy-
alinosis. After prophylactic administration of either 
losartan or NO2-OA, marked statistically significant 
improvement in vascular congestion occurred with 
only few congested blood capillaries and minimal 
extravasation still noticed in the pre-DN NO2-OA 
group. Vascular congestive features on the other hand 
showed only minimal amelioration in both post DN 
treated losartan and NO2-OA groups.
Examination of PAS stained sections (Fig. 4). 
Diabetic rats displayed features of glomerulosclerosis 
manifested by excessive mesangial matrix deposition 
causing obliteration of the capillary lumina. Glomer-
ular tuft adhesion, Bowman’s capsule thickening 
and loss of the apical brush border of renal tubules 
were also predominant features in the DN group. 
Prophylactic losartan resulted in preservation of the 
tubular brush border with normal tubular basal lam-
inae, while prophylactic NO2-OA showed only partial 
protection with areas of normal PAS reaction and 
others of focal thickening. Administration of either 
losartan or NO2-OA after induction of DN showed 
persistence of Bowman’s capsule and capillary tuft 
basement membrane thickening in the losartan group 
and failure to restore the degenerated tubular brush 
border in the NO2-OA group.
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Figure 1. A. Fasting serum glucose; B. Systolic blood pressure (SBP); C. Albumin in urine (urine albumin excertion [UAE]); D. Glomerular 
filtration rate (GFR); E. Urea; F. Serum angiotensin; G. Parathyroid hormone related protein (PTHrP) expression in renal tissue among studied 
groups; H. Tubular necrosis score; I. Tubular cast score. Each vertical bar represents the mean ± standard deviation of 10 animals; *Statis-
tically significant compared to control group; #Statistically significant compared to DN group; $Statistically significant compared to pre-DN 
losartan group; &Statistically significant compared to post-DN losartan group; DN — diabetic nephropathy; NO2-OA — nitro-oleic acid;  
pre-DN — pre-diabetic nephropathy; pre-DN NO2-OA — pre diabetic nepropathy nitro-oleic acid; post-DN — post-diabetic nephropathy; 
post-DN NO2-AO — post diabetic nepropathy nitro-oleic acid.
84
Folia Morphol., 2019, Vol. 78, No. 1
Figure 2. Parathyroid hormone related protein (PTHrP) correlation studies showing a strong positive correlation with PTHrP and angiotensin 
(A), urea (B) and urinary albumin excretion (UAE) (C) and negative correlation with glomerular filtration rate (GFR) (D).
Examination of MT stained sections (Fig. 5). 
The DN group displayed features of diabetic glomer-
ulosclerosis and tubulointerstitial fibrosis. The pre-DN 
losartan group showed normal collagen distribution 
pattern around renal tubules and in the glomeruli 
except for localised areas of tuft-to-capsule adhe-
sions, while pre-DN NO2-OA group showed partial 
conservation of the capillary lumina with occasional 
focal collagen deposition. Losartan treatment resulted 
in recovery from the glomerular sclerotic pattern but 
with compensatory tuft hypertrophy while treatment 
with NO2-OA resulted in non-significant improve-
ment in glomerulosclerosis.
Histomorphometric parameters (Table 1)
Assessment of glomerular parameters showed 
significant improvement with prophylactic losartan 
and NO2-OA while the treatment groups on the other 
hand showed non-significant differences relative to 
the diabetic group. Regarding tubular parameters, 
the tubular diameter and tubular epithelial height 
showed significant increase in pre-DN losartan, pre-
DN NO2-OA, and post-DN losartan groups, while the 
bush border length demonstrated significant increase 
only with pre-DN losartan.
DISCUSSION
This study has been designed to compare the 
possible preventive and therapeutic effect of losartan 
and NO2-OA on DN, and to evaluate their effects on 
PTHrP modulation in the kidney of diabetic rats. 
The DN group in the current study demonstrated 
various functional changes in the form of deteriora-
tion of renal functions and significant elevation of 
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Figure 3. A. Control group showing normal renal corpuscle composed of a normal glomerulus (G) formed of capillary tuft surrounded by 
Bowman’s space (S); MD — macula densa; P — PCT; D — DCT; B. DN group showing mesangial matrix deposition (Mx), extra-glomerular 
mesangial expansion (arrow head), congestion of glomerular capillaries with occasional aneurysmal dilatation (arrows) and widening of 
urinary space (S) secondary to capillary tuft retraction. Some tubules show intraluminal exfoliation of epithelial cells (curved arrows); others 
appear obliterated (O) with casts; C. Pre-DN losartan group showing preservation of the glomerular (G) architectural patterns. Most of the tu-
bules (T) appear healthy with vesicular nuclei and prominent nucleoli (arrows); D. Pre-DN NO2 group showing glomerulus (G) with moderately 
increased mesangial matrix. Some tubules (T) are degenerated, others appear normal (N); E. Post-DN losartan group showing glomerulus with 
tuft-to-capsule adhesion (Ad) (synechiae) and slight increase in mesangial matrix (Mx). Normal macula densa (MD) is observed; F. Post-DN 
NO2-OA group showing glomerulus (G) with mesangial hypercelluarity. Few tubules (T) appear filled with casts. H&E × 400; Scale bar 50 μm;  
G, H, I, J, K, L, M showing vascular changes. G. Control group showing normal vascular pattern; H. DN group showing severely dilated con-
gested blood vessels (BV) surrounded by hyalinosis; I. Pre-DN losartan group showing obvious improvement of vascular congestion; J. Pre-DN 
NO2-OA group showing few congested blood vessels in addition to blood extravasation (E); K. Post-DN losartan group showing markedly  
dilated congested BV; L. Post-DN NO2-OA group displaying obviously dilated congested BV in close vicinity of a glomerulus and surrounded 
by extra-glomerular mesangial cell expansion; M. Graph showing area per cent of vascular congestion in different groups; data are presented 
as mean ± standard deviation (p < 0.05 in DN vs. control, Pre-DN losartan vs. DN and Pre-DN NO2-OA vs. DN); *Statistically significant 
compared to control, #Statistically significant compared to DN; G, H: ×100; Scale bar 200 μm; I, J, K: ×400; Scale bar 50 μm, L: ×200; 
Scale bar 50 μm); DN — diabetic nephropathy; NO2-OA — nitro-oleic acid; pre-DN — pre-diabetic nephropathy; pre-DN NO2-OA — pre-dia-
betic nephropathy nitro-oleic acid; post-DN — post-diabetic nephropathy; post-DN NO2-OA — post-diabetic nephropathy nitro-oleic acid.
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Figure 4. Periodic acid-Schiff (PAS) stained sections of: A. Control group showing positive PAS reaction in the intact apical brush border 
(arrow heads) and basement membrane of the renal tubules (thin arrows) and capillary basement membrane (thick arrows); B. DN group 
showing excessive mesangial matrix (Mx) deposition (Early stages of Kimmelstiel-Wilson lesion) causing obliteration of the capillary lumina 
and tuft adhesion (Ad) to Bowman’s capsule. Areas of focal thickening of the parietal layer of Bowman’s capsule (B), loss of the apical brush 
border of renal tubules (T), thickening of the basal membrane of macula densa (curved arrow) and walls of blood vessels (arrow heads) and  
a degenerated glomerulus (G); C. Diabetic rats adrenal medulla displaying thickening of the basement membrane (arrows) of collecting tu-
bules (C), loop of Henle (H) and blood vessels (BV); D. Pre-DN losartan group showing restoration of tubular brush border (arrow heads) with 
normal thin tubular basal laminae (arrows); E. Pre-DN NO2-OA group showing glomeruli with areas of normal PAS reaction (arrow heads), oth-
ers with localised thickening (curved arrows). The Bowman’s capsule shows few areas of focal thickening (thick arrow) and others of normal 
thickness (thin arrow); F. Post-DN losartan group showing thickened Bowman’s capsule (curved arrow) and glomeruli with thickened capillary 
tuft basement membranes (arrow heads) with tuft-to-capsule adhesions (Ad); G. Post-DN NO2-OA group showing hypertrophied glomerulus 
(G) almost filling the Bowman’s space and surrounded by thin corrugated Bowman’s capsule (arrow). Most of the tubules exhibit degenerated 
brush border; H. Graph showing optical density of PAS in different groups; data are presented as mean ± standard deviation (p < 0.05 in DN 
vs. control, Pre-DN losartan vs. DN, Pre-DN NO2-OA vs. DN, Post-DN losartan vs. DN and Post-DN NO2-OA vs. DN; *Statistically significant 
compared to control; #Statistically significant compared to DN; PAS ×400; Scale bar 50 μm; DN — diabetic nephropathy; NO2-OA — nitro- 
-oleic acid; pre-DN — pre-diabetic nephropathy; pre-DN NO2-OA — pre-diabetic nephropathy nitro-oleic acid; post-DN — post-diabetic  
nephropathy; post-DN-NO2-OA — post-diabetic nephropathy nitro-oleic acid.
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Figure 5. A. Control group demonstrating normal collagen distribution; B. DN group displaying sclerosed glomeruli with extensive collagen 
deposition (arrows) causing marked implosion of the capillary loops. Some glomeruli appear severely collapsed (C); others show tuft-to- 
-capsule adhesion (arrow heads); C. DN group showing tubulointerstitial fibrosis; D. Pre-DN losartan group showing preservation of normal 
collagen distribution around renal tubules and in the glomeruli except for few localised areas of tuft-to-capsule adhesions (arrow heads). Thin 
but irregular Bowman’s capsule (B) is observed; E. Pre-DN NO2-OA group showing partial conservation of the capillary lumina (arrows) and 
focal area of increased collagen deposition (arrow head); F. Post-DN losartan group displaying recovery from the glomerular sclerotic pattern 
but with compensatory tuft hypertrophy and capsule adhesions (arrow head). Collagen bundles in the parietal layer of the Bowman’s capsule 
show areas of thickening (thick arrow) as well as areas of rarefaction (thin arrow); G. Post-DN NO2-OA group showing few open capillary 
loops (arrows) in the sclerotic glomeruli and deposition of few thickened collagen bundles in the Bowman’s capsule (arrow head); H. Graph 
showing area per cent of collagen deposition in different groups; data are presented as mean ± standard deviation (p < 0.05 in DN vs.  
control, Pre-DN losartan vs. DN, Pre-DN NO2-OA vs. DN and Post-DN losartan vs. DN; *Statistically significant compared to control;  
#Statistically significant compared to DN; Masson trichrome ×400; Scale bar 50 μm; DN — diabetic nephropathy; NO2-OA — nitro-oleic acid; 
pre-DN — pre-diabetic nephropathy; pre-DN NO2-OA — pre-diabetic nephropathy nitro-oleic acid; post-DN — post-diabetic nephropathy; 
post-DN NO2-OA — post-diabetic nephropathy nitro-oleic acid.
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Table 1. Histomorphometric parameters
Control DN Pre-DN losatan Pre-DN NO2-OA Post-DN losatan Post-DN NO2-OA
Bowman’s space [μm2] 1756.16 ± 41.30 3007.50 ± 15.14 
(p = 0.007)**
2053.06 ± 66.01 
(p = 0.024)*
2416.17 ± 25.11 
(p = 0.043)*
2524.12 ± 81.31 
(p = 0.051)NS
2991.57 ± 39.18 
(p = 1.65)NS
Glomerular area [μm2] 3123.18 ± 91.43 2001.61 ± 54.02 
(p = 0.042)*
2769.34 ± 81.15 
(p = 0.01)**
2309.16 ± 76.44 
(p = 0.49)*
2187.16 ± 46.02 
(p = 0.66)NS
2052.75 ± 71.09 
(p = 3.02)NS
Tubular diameter [μm2] 39.87 ± 2.79 22.28 ± 3.1 
(p = 0.021)*
33.12 ± 4.07 
(p = 0.032)*
27.63 ± 5.61 
(p = 0.041)*
29.88 ± 2.09 
(p = 0.037)*
25.18 ± 1.49 
(p = 0.07)NS
Tubular epithelial height [μm] 19.72 ± 2.66 8.84 ± 3.19 
(p = 0.036)* 
15.63 ± 2.44 
(p = 0.012)*
12.02 ± 1.71 
(p = 0.042)*
11.25 ± 2.13 
(p = 0.047)*
9.28 ± 1.51 
(p = 0.09)NS
Length of the brush border [μm] 0.82 ± 0.06 0.41 ± 0.01 
(p = 0.041)*
0.65 ± 0.08 
(p = 0.04)*
0.50 ± 0.02 
(p = 0.062)NS
0.54 ± 0.07 
(p = 0.058)NS
0.48 ± 0.02 
(p = 1.68)NS
*Significant; **Highly significant; NS — non significant; DN — diabetic nephropathy; NO2-OA — nitro-oleic acid; pre-DN — pre-diabetic nephropathy; pre-DN NO2-OA — pre-diabetic 
nephropathy nitro-oleic acid; post-DN — post-diabetic nephropathy; post-DN-NO2-OA — post-diabetic nephropathy nitro-oleic acid. P values for pre-DN Losatan, pre-DN NO2-OA, post
-DN losatan and post-DN NO2-OA are calculated relative to the DN group. P values for DN group are calculated relative to the control group. Ten randomly chosen, non-overlapping fields 
(200×) was as follows: 0 (none), 1 (≤ 10%), 2 (11–25%), 3 (26–45%), 4 (46–75%), and 5 (≥ 76%).
SBP which proved the development of hypertension 
with DN. This latter finding coincides with the previ-
ous reports of increased incidence of hypertension in 
patients of DN [18]. Systemic hypertension has been 
also previously reported to cause intraglomerular 
hypertension leading to glomerular hypertrophy and 
injury [17]. Marked obliteration of the glomerular 
capillary tuft secondary to excessive collagen and 
mesangial matrix deposition demonstrated in our 
study readily suggests the occurrence of glomerular 
hypertension in DN group. 
Parathyroid hormone related protein expression 
in renal tissues and serum angiotensin were also 
significantly higher in the DN group in the current 
study. This adds further evidence to the previous 
reports demonstrating the involvement of PTHrP 
overexpression in renal injury [6]. Our work also 
agrees with previous studies that suggested the 
involvement of PTHrP in the mechanisms related 
to AngII-induced renal injury [2, 15]. Furthermore, 
exogenously administrated AngII, by its AT1R, in-
creases PTHrP expression in glomerular and tubular 
cells as well as in vascular smooth cells both in vivo 
and in vitro. Interestingly, PTHrP in the current study 
showed a strong positive correlation with angio-
tensin, urea and UAE and negative correlation with 
GFR. These results are concordant with the previous 
studies reporting overexpression of PTHrP in the 
renal tubules and glomeruli in diabetic mice, which 
was associated significantly with increased UAE [8]. 
The authors also reported increase in the risk of 
developing proteinuria in mice with higher PTHrP 
levels. This also agrees with our results that PTHrP 
was involved in renal injury associated with DN.
The current study evaluated the possible preventive 
and therapeutic effects of losartan and NO2-OA on the 
functional and histopathological parameters of DN. 
Administration of losartan as ARB either pre-DN 
or post-DN showed significant improvement in SBP 
and fasting serum glucose level compared to diabetic 
group, with more improvement in pre-DN group. 
Concordant results have been previously reported 
[26]. This hypoglycaemic effect of losartan could 
be due to the effect of losartan in increasing insulin 
sensitivity and b-cell responsiveness to glucose and 
also through enhancement of glucose homeostasis 
through several insulin signalling pathways [10]. This 
effect was suggested to occur at the levels of both 
tyrosine phosphorylation and phosphatidylinositol 
3-kinase activation as well as mitogen-activated pro-
tein kinase [1].
Our results also showed that pre-DN losartan sig-
nificantly improved kidney function and was even 
more effective than post-DN losartan regarding urea, 
UAE and GFR with a significant difference concerning 
UAE. These observations are concordant with the 
previous studies reporting reduction in progression 
of DN with losartan [24]. Our study has provided an 
in-depth histopathological analysis of these observa-
tions demonstrating increment in tubular epithelial 
height, improvement in tubular lining with predom-
inance of vesicular nuclei with prominent nucleoli 
and significant reduction in glomerular and tubular 
injury markers. Taken together, these data along with 
the previous histopathological reports [9] provide 
considerable support for the view that the hallmark 
features of renal damage including glomerulosclerosis 
and renal tubular necrosis occur as a result of intense 
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intrarenal vasoconstriction subsequent to renin–an-
giotensin activation [5, 22].
The renoprotective effect of losartan as an ARB 
may be due to blood pressure reduction and increase 
in renal blood flow with reduction in intra-glomerular 
pressure [11]. This was evidenced in the current study 
by conservation of the glomerular capillary lumina, 
reversion of the glomerular sclerosis pattern, reces-
sion of mesangial proliferation and improvement of 
vasculopathy in losartan-treated groups relative to 
their diabetic counterparts.
In the current study, administration of losartan 
resulted in significant decrease in PTHrP levels. These 
results support the view that AngII-induced renal 
damage is associated with renal PTHrP upregulation 
[6] and that AngII increases PTHrP expression in glo-
merular and tubular cells both in vivo and in vitro [3].
NO2-OA administration showed a significant de-
cline in fasting serum glucose level in both pre-DN 
and post-DN groups relative to DN group, with more 
improvement in pre-DN group. SBP was also im-
proved significantly after pre- and post-DN NO2-OA 
administration with non-significant difference be-
tween both groups. Our data showed improvement in 
kidney function and glomerular damage parameters 
only in pre-DN NO2-OA rats versus diabetic rats with 
non-significant effect with post-DN NO2-OA rats. 
This could be explained by the actual occurrence of 
DN pathological changes interfering with maximum 
beneficial effect of the drug.
NO2-OA has been previously reported to induce 
non-significant reduction in diabetic glomerulosclero-
sis [12]. This adds further support to lack of complete 
resolution of the sclerotic pattern observed in the 
glomeruli of DN group following NO2-OA adminis-
tration in our study.
There is a lack of studies concerning the relation 
of NO2-OA with PTHrP. This work showed a signifi-
cant reduction in both serum angiotensin and PTHrP 
after NO2-OA administration with a more significant 
decline in pre-DN group. This effect may be due to 
reduction of AT1R mRNA level and gene expression 
with subsequent angiotensin reduction [23] or due 
to binding to AT1R, which further reduces hetero-
trimeric G-protein coupling, and inhibits IP3 (ino-
sitol-1,4,5-triphosphate) and calcium mobilisation, 
without inhibiting AngII binding to the receptor [27].
The current study offers losartan and nitro-oleic 
acid as promising lines for enhancing renal sparing 
and maintaining functional integrity of the kidneys 
in the diabetic patients. The two drugs, especially 
losartan, can be suggested as prophylactic agents to 
prevent the deleterious effect of diabetic nephropathy 
and its undesired consequences of glomerulosclerosis 
and tubular injury.
Although the results of the current study suggest 
the superiority of losartan over nitro-oleic acid in 
ameliorating diabetic nephropathy, yet, the current 
study used a rat model, and dissimilar outcome in 
humans could be a possibility. Thus, generalisations 
cannot be made. Also, in a future study, additional 
testing with larger sample sizes and/or changes to the 
dosage of losartan and nitro-oleic acid could more 
precisely determine the significant difference between 
the studied groups, especially in the post-diabetic 
nephropathy groups.
CONCLUSIONS
Both losartan and NO2-OA were found to improve 
DN. This study postulated that there is no difference 
in the preventive effect of both drugs in improving 
hyperglycaemia and elevated SBP as well as in im-
proving kidney function and tubular injury. However, 
therapeutic effect of losartan on DN may be more 
beneficial than NO2-OA effect especially in alleviating 
diabetes-induced vasculopathy and glomerulosclero-
sis. Moreover, our data highlight the potential role of 
AngII antagonist in protection and regression of DN 
and reduction in PTHrP overexpression supporting 
the previously reported role of AngII in regulating 
PTHrP expression. 
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